This same strategy has been applied in a transgenic HCC mouse model combining anti-PD-1 blockade with the synergic stimulation of two positive co-stimulatory molecules (4-1BB and tumor necrosis factor receptor superfamily, member 4 (OX40)). The gene discussed is TNFRSF4; the disease is hepatocellular carcinoma.